glp 1 receptor agonists are contraindicated in Glucagon-like peptide agonist use and risk of thyroid cancer: Scandinavian cohort study Benefits and Risks of GLP-1
Description
Role of renal sympathetic nerves in GLP-1 (glucagon-like peptide-1) receptor agonist exendin-4-mediated diuresis and natriuresis in diet-induced obese rats
Ongoing trials are investigating conditions, including Alzheimers disease, alcohol use disorder and metabolic dysfunction-associated steatohepatitis (MASH)
Based on their test results and an initial consultation, a doctor may prescribe patients to start off with a low dosage of GLP-1s that is slowly ramped up over time to meet the desired dosage amount
0866 Prevalence of obesity in obstructive sleep apnea within a large community-based cohort of middle-aged/older adults
Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by abeta and iron
JAMA 2024;332(12):970978
